7-Substituted fused ring tetracycline compounds
View Patent ↗7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.
1. A method for treating a tetracycline responsive state in a mammal, comprising administering to said mammal a 7-substituted fused ring tetracycline compound of formula (I):
wherein:
X is CR 6 R 6′ ;
R 4 and R 4′ are each alkyl;
R 5 is hydrogen or hydroxyl;
R 6 and R 6′ are each independently hydrogen, hydroxyl, alkyl, or taken together, alkenyl;
Y and Y′ are each independently optionally substituted C, N, O, or S;
m is 1 or 2; and pharmaceutically acceptable salts thereof; such that the tetracycline responsive state is a bacterial infection that is selected from the group consisting of S. pnuemoniae, E. hirae, H influenzae , and M catarrhalis.
2. The method of claim 1 wherein R 5 , R 6 and R 6′ are each hydrogen and R 4 and R 4′ are each methyl.
3. The method of claim 1 , wherein Y and Y′ are each oxygen.
4. The method of claim 1 , wherein m is 1.
5. A method for treating a tetracycline responsive state in a mammal, comprising administering to said mammal 7-(3′,4′-methylene dioxyphenyl)sancycline or a pharmaceutically acceptable salt thereof, such that the tetracycline responsive state is a bacterial infection that is selected from the group consisting of S. pnuemoniae, E. hirae, H influenzae , and M catarrhalis.
6. The method of claim 2 , wherein said bacterial infection is associated with S. pnuemoniae.
7. The method of claim 2 , wherein said bacterial infection is associated with E. hirae.
8. The method of claim 2 , wherein said bacterial infection is associated with H influenzae.
9. The method of claim 2 , wherein said bacterial infection is associated with M catarrhalis.
10. The method of claim 2 , wherein said bacterial infection is resistant to other tetracycline antibiotics.
11. The method of claim 2 , wherein said compound is administered with a pharmaceutically acceptable carrier.
12. The method of claim 5 , wherein said bacterial infection is associated with S. pnuemoniae.
13. The method of claim 5 , wherein said bacterial infection is associated with E. hirae.
14. The method of claim 5 , wherein said bacterial infection is associated with H influenzae.
15. The method of claim 5 , wherein said bacterial infection is associated with M catarrhalis.
16. The method of claim 5 , wherein said bacterial infection is resistant to other tetracycline antibiotics.
17. The method of claim 5 , wherein said compound is administered with a pharmaceutically acceptable carrier.